Inhibition of pristane-induced peritoneal plasmacytoma formation.
While the mechanism of how Indo inhibits PCTGEN is not established, Several hypothetical explanations provide new potential experimental approaches. Indo may block production of cytokines such as Il-6 in accessory cells that are critical for B-cell growth, viability and maturation, or it may directly target B cells via PPAR-gamma receptors. The latter mode of action is described in other cell types but not yet defined in B cells.
Laboratory of Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
M
M
Potter
L
L
Kutkat
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology; D001402:B-Lymphocytes / Q000187:drug effects / Q000276:immunology; D002273:Carcinogens / Q000633:toxicity; D007213:Indomethacin / Q000494:pharmacology; D015850:Interleukin-6 / Q000494:pharmacology; D051379:Mice; D008817:Mice, Mutant Strains; D010534:Peritoneal Neoplasms / Q000139:chemically induced / Q000276:immunology / Q000517:prevention & control*; D010954:Plasmacytoma / Q000139:chemically induced / Q000276:immunology / Q000517:prevention & control*; D013047:Specific Pathogen-Free Organisms; D013729:Terpenes / Q000633:toxicity
D000894:Anti-Inflammatory Agents, Non-Steroidal; D002273:Carcinogens; D015850:Interleukin-6; D013729:Terpenes; C009042:pristane; D007213:Indomethacin